Index

Note: page numbers in italics refer to figures; page numbers in bold refer to tables.

acquired immunodeficiency disorders, 132, 214
acquired platelet disorders, 220
acute basophilic leukaemia, 58
CD25 expression in, 66
differentiation from HLA-DR-negative AML, 67
MPO expression in, 66
acute erythroid leukaemia (AML M6), 57, 74, 77
diagnosis, 52
differentiation from APL, 67
MPO expression in, 66
acute leukaemia (AL), 43–99
ambiguous lineage, 53–4, 54
blast cell characteristics, 46–50
blast cell populations, 45–6
central nervous system disease in, 88–92, 90–1
clinical presentation and sampling, 44
definition and classification, 43–4, 44
tenumeration of blast cells, 51–2
gating strategies, 46–9
genetic correlation, 46, 83–4
lineage assignment, 52–4
minimal residual disease, 184
morphological correlation, 45–6, 51–2
neoplastic precursor cell identification, 45–52
not otherwise specified, 67
with NPM 1 and/or FLT 3 ITD mutation, 67
precursor antigen expression patterns, 50–1
precursor cell antigens, 48
see also acute lymphoblastic leukaemia/lymphoma (ALL); acute myeloid leukaemia (AML)
acute lymphoblastic leukaemia/lymphoma (ALL), 38–9, 77–92
CNS involvement, 147
lineage assignment, 53
minimal residual disease, 187–99
serous effusions, 89, 146
UKALL National Trials, 35, 188, 189
see also B-cell acute lymphoblastic leukaemia/lymphoma (B-ALL); T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL)
acute mast cell leukaemia, 167
CD2 expression in, 59
CD25 expression in, 66
MPO expression in, 66
acute megakaryoblastic leukaemia (AML M7), 56, 58, 74, 78–9
differentiation from APL, 67
MPO expression in, 66
acute monoblastic/monocytic leukaemia (AML M5), 57, 74
CD4 expression in, 61
CD5 expression in, 65
CD56 expression in, 65
differentiation from CMML, 165
MPO expression in, 66
worked examples, 75–6
acute myeloid leukaemia (AML), 52–3, 54–77
aberrant and asynchronous antigen expression, 55–66, 56–8
AML M0, 57, 62–3
AML M1, 57, 63, 64
AML M2, 57, 63–4, 65
AML M3 see acute promyelocytic leukaemia (APL) (AML M3)
AML M4 see acute myelomonocytic leukaemia (AML M4)
AML M4EO, 46, 59, 61, 64
AML M5 see acute monoblastic/monocytic leukaemia (AML M5)
AML M6 see acute erythroid leukaemia
AML M6 see acute megakaryoblastic leukaemia (AML M7)
antigenic patterns of particular significance, 66
CD2 expression in, 59
CD4 expression in, 59, 61
CD5 expression in, 65, 66
CD7 expression in, 63
CD19 expression in, 63–4
CD25 expression in, 66
CD34-negative HLA-DR-negative, 66–7
CD56 expression in, 64–5
leptomeningeal disease in, 89
lineage assignment, 52–3
minimal residual disease, 186–7
precursor antigen expression, 45–6, 50
subtypes by flow, 56–8, 67, 74, 77
with t(8;21) (AML M2), 56, 63, 64
TdT expression in, 64
acute myelomonocytic leukaemia (AML M4), 57
CD34 expression in, 26, 31
differentiation from B-ALL, 45–6
immunophenotypic profile, 46
acute panmyelosis with myelofibrosis, 58
acute promyelocytic leukaemia (APL) (AML M3), 56, 67
CD2 expression in, 59
CD4 expression in, 61
CD34 expression in, 66
CD56 expression in, 65
CD117 expression in, 33
MPO expression in, 66
worked examples, 68–9, 69–70
acute T-cell leukaemia/lymphoma (ATL), 131–2, 135
acute undifferentiated leukaemia (AUL), 53–4, 54
aerolin, 203
AITL (angio-immunoblastic T-cell lymphoma), 133–6, 135
ALCL (anaplastic large cell lymphoma), 132–3, 134, 135
alignment beads, 16–17
ALK (anaplastic lymphoma kinase), 133
ALL see acute lymphoblastic leukaemia/lymphoma (ALL)
allele specific oligonucleotide PCR (ASO-PCR), 186
amyloidosis, primary, 174–5
anaplastic large cell lymphoma (ALCL), 132–3, 134, 135
anaplastic lymphoma kinase (ALK), 133
angio-immunoblastic T-cell lymphoma (AITL), 133–6, 135
antibody binding, 27–8
anticoagulants, 20–1
antigen selection, 27, 48

Practical Flow Cytometry in Haematology Diagnosis, First Edition. Mike Leach, Mark Drummond and Allyson Doig.
© 2013 John Wiley & Sons, Ltd. Published 2013 by John Wiley & Sons, Ltd.

243
Index

244

antiplatelet drug therapy, 220–1

A PL see acute promyelocytic leukaemia (APL)

aplastic anaemia, 158–9, 207, 233, 233

apoptosis, 21, 23, 24

arterial thrombotic disease, 220

ASO-PCR (allele specific oligonucleotide PCR), 186

asymptomatic myeloma, 174

asynchronous antigen expression, 59

ATL (acute T-cell leukaemia/lymphoma), 131–2, 135

AUL (acute undifferentiated leukaemia), 53–4, 54

auto-fluorescence, 27

auto-immune diseases, 136, 202, 229, 231

auto-immune haemolytic anaemia (AIHA), 104

B prolymphocytic leukaemia (B PLL), 108, 110

CD5 expression in, 114

differentiation from MCL, 106

back gating, 13, 14

background fluorescence, 27–8

BAL (bronchoalveolar lavage) specimens, 238

background fluorescence, 27–8

back gating, 13, 14

B prolymphocytic leukaemia (B PLL), 108, 110

B-cell acute lymphoblastic leukaemia (B-ALL), 45, 77, 81–3, 81, 82

aberrant antigen expression, 83

CD5 expression in, 119, 121

differentiation from AML, 45

differentiation from Burkitts, 119

gene rearrangements, 82, 83

minimal residual disease, 191–3, 191, 194–5

subtypes by flow, 83–4, 84

worked example, 85–6

B-cell lymphoproliferative disorders, 101–25

antigen selection, 102

CD5 positive, 102–15, 114

B prolymphocytic leukaemia, 108, 110

chronic lymphocytic leukaemia (CLL), 102–5

diffuse large B-cell lymphoma (DLBCL), 119

diffuse large B-cell lymphoma (DLBCL), 118

follicular lymphoma (FL), 116–18

hairy cell leukaemia (HCL), 121

summary table, 121

identification and diagnosis, 101–2

CD5 positive, 102–15

CD10 positive, 116–21

extended B-cell panel, 121–5

B-cells

fluorescence intensity, 8

lymphomas, 22, 25–6, 38–9

maturation processes, 35–6

normal cell populations, 100–1

BCR-ABL negative myeloproliferative neoplasms, 166–70

Bernard Soulier syndrome, 220, 220

bilineage AL, 53

Binet staging system for CLL, 103

biphenotypic AL, 53

BL see Burkitt leukaemia/lymphoma (BL)

blast cell, 45

blastic plasmacytoid dendritic cell neoplasm, 45

haematogones, 233

leukaemia, 233

normal cell populations, 100–1

myeloid maturation processes, 35–6

lymphomas, 22, 25–6, 38–9

maturation processes, 35–6

normal cell populations, 31–42

myeloid expansions, 231–2

maturation arrest, 232–3

myeloid expansions, 231–2

myeloid maturation processes, 34

normal cell populations, 31–42

reactions to various disease states and non-neoplastic reactions, 231–6

regenerating, 25, 32, 51

response to non-haemopoietic tumours, 233–6

bone marrow aspirates, 21–3, 28

bronchoalveolar lavage (BAL) specimens, 238

Burkitt leukaemia/lymphoma (BL), 118–19

CD10 expression in, 121

CNS involvement, 147

differentiation from B-ALL, 46, 83

Ig expression in, 50

serous effusions, 146

worked example, 120–1

calibration, 15–18

calibration beads, 18

carcinoma, 233–9, 237

cardiovascular disease, 220

cell ageing and apoptosis, 21

central nervous system (CNS) disease, 88–92, 90–1

cerebro-spinal fluid (CSF), 238–40

analysis, 23–5

examination, 88–92

flow cytometric assessment, 146–9

identification of overt central nervous system disease, 147

identification of subclinical disease, 147–9

sampling, 89

certified blank, 16

CGD (chronic granulomatous disease), 215, 215

chromosomal translocations, detection by flow, 92–3

chronic eosinophilic leukaemia, 166

chronic granulomatous disease (CGD), 215, 215

chronic lymphocytic leukaemia (CLL), 102–5

Binet staging system, 103

CD5 expression in, 114

clonal lymphoid populations, 101

cytogenetics, 105, 105

diagnosis of B-cell disorders, 101–2

differentiation from B PLL, 108, 110

and DLBC, 113

identification of clonal B-cell disorders, 101

immunophenotype, 104, 105, 186

minimal residual disease, 185–6

morphology, 103, 104

relative incidence, 123

Richter transformation, 113–14, 114–15

chronic lymphoproliferative disorders (LPD), 100–45

CD30 positive, 145, 145

cerebro-spinal fluid, 146–9

identification and diagnosis of clonal B-cell disorders, 101–2, 102

CD5 positive B-cell lymphoproliferative disorders, 102–15

CD10 positive B-cell lymphoproliferative disorders, 116–21

using an extended B-cell panel, 121–5

identification of clonal lymphoid populations, 101

identification of T-cell lymphoproliferative disorders, 125–8

CD4 positive T-cell disorders, 128–36

CD4/8 negative disorders, 141–5

CD4/8 positive T-cell disorders, 141

CD8 positive T-cell disorders, 136–41

normal peripheral blood lymphoid populations, 100–1

serous effusions, 146

chronic myeloid leukaemia (CML), 165–6

basophils in, 35

CD19 expression in, 63

diagnosis, 152

differentiation from AL, 43

eosinophils in, 35

HLA-DR expression in, 67

chronic myelomonocytic leukaemia (CMML), 163–5

chronic neutrophilic leukaemia, 166

chylos effusions, 146

clinical issues, 20, 28

CLL see chronic lymphocytic leukaemia (CLL)

CML see chronic myeloid leukaemia (CML)

CMML (chronic myelomonocytic leukaemia), 163–5

CNS (central nervous system) disease, 88–92, 90–1
common variable immunodeficiency (CVID), 231
congenital myeloperoxidase (MPO) deficiency, 215
countour plot, 11, 12
control materials, 15
cryohydrocytosis, 209
cSF see cerebro-spinal fluid (CSF)
cutaneous T-cell lymphoma (CTCL), 126, 128–9
CVID (common variable immunodeficiency), 231
cytogenetics
cytometrist training, 25–7
cytospin preparations, 24, 25
data display, 9–18
data quality, 15–18
diffuse large B-cell lymphoma (DLBCL), 118
CD10 expression in, 121
chemotherapy, 146
CNS involvement, 147–8
immunophenotype, 118
serous effusions, 146
diffuse large B-cell lymphoma, Richter type (DLBCL), 113–14, 114–15
direct staining method, 3–4
DLBCL see diffuse large B-cell lymphoma (DLBCL)
DNA analysis, 5
dot plots, 11, 12
Down’s syndrome, 58, 65
Dusseldorf Prognostic Score for myelodysplastic syndromes, 163
dyes, fluorescence, 6–7
early T-precursor phenotype (ETP), 86
EATL (enteropathy associated T-cell lymphoma), 142, 144, 145
EBV (Epstein Barr virus), 226
EDTA (ethylenediaminetetraacetic acid), 20–1
effusions see serous effusions
EGIL (European Group for Immunophenotyping of Leukaemias), 44, 77, 81, 82
electronic systems, 9
EMEA (eosin-5-maleimide) fluorescence, 209, 211
enteropathy associated T-cell lymphoma (EATL), 142, 144, 145
eosin-5-maleimide (EMEA) fluorescence, 209, 211
eosinophilia
in ATL, 132
in CML, 165
pleural effusions, 238
eosinophilia (AML M4Eo), 46, 59, 61, 64
eosinophilic leukaemia see chronic eosinophilic leukaemia
eosinophils, 33, 35
differentiation, 6
in serous effusions, 238
Epstein Barr virus (EBV), 226
errors in sample handling, 26
eythrocytes, 22, 25
eythroid leukaemia see acute erythroid leukaemia (AML M6)
eythroid maturation, 35
eythroleukaemia see acute erythroid leukaemia (AML M6)
esential thrombocytopenia, 166
ethylenediaminetetraacetic acid (EDTA), 20–1
ETP (early T-precursor phenotype), 86
European Group for Immunophenotyping of Leukaemias (EGIL), 44, 77, 81, 82
exercise induced lymphocytosis, 226, 228
FAB acute leukaemia classification, 43, 77
FALS (forward angle light scatter), 5
FITC see fluorescein isothiocyanate (FITC)
FL see follicular lymphoma (FL)
FLAER (proaerolysin variant), 203, 205, 206, 207
flow rate and sample pressure, 5
fluidics system, 4–5
fluorescein isothiocyanate (FITC)
maximum excitation and emission wavelengths, 7
spectral overlap, 9, 10
fluorescence, 6–8
fluorescence intensity, 8
fluorescence/SSC plots, 13, 15, 16
fluorochrome binding, 27–8
fluorochromes, 6–8
excitation max and emission max, 7
selection, 27
spectral overlap, 9, 10
foetal maternal haemorrhage (FMH), 213–14
follicular lymphoma (FL), 116–18
CD10 expression in, 121
serous effusions, 146
forward angle light scatter (FALS), 5
forward scattered light (FSC), 5, 6
leucocyte differentiation, 6, 11
gating strategies, 12–15, 26–7, 46–9
G-CSF (granulocyte colony stimulating factor), 231–2
Genetic abnormalities, identifying by flow, 92–3
Glanzmann’s thrombasthaenia, 220
glycosyl phosphatidylinositol (GPI), 202–3,
203, 204
granulocyte colony stimulating factor (G-CSF), 231–2
granulocyte disorders, 215–19, 215
granulocytes, 155
analysis, 205, 206
anticoagulants, 21
apoptosis, 21
differentiation, 11
granulomatous disease see chronic granulomatous disease (CGD)
haematogones, 36–41, 196, 233
Haematology Malignancy Diagnostic Service (HMDS), 28–9
haematopoietic progenitor cells, 31–3
haematopoietic stem cell (HSC) disorders, 152, 202
haematopoietic stem cells (HSC), 31, 214–15
haemolytic disease of the newborn (HDN), 213
hairey cell leukaemia (HCL) autfluorescence, 27
CD10 expression in, 121, 121
differentiation from SMZL, 108
identified using an extended B-cell panel, 102, 122–3, 124
relative incidence, 123
summary table, 125
hairey cell leukaemia variant (HCL-V), 123, 125
handling errors, 26
HCL see hairy cell leukaemia (HCL)
HDN (haemolytic disease of the newborn), 213
heparin, 21
hepatosplenetic T-cell lymphomas (HSTCL), 139–41, 145
hereditary elliptocytosis, 209, 210, 211
hereditary functional granulocyte disorders, 215–19, 215
hereditary platelet disorders, 219–21
hereditary pyropoikilocytosis, 209, 210
hereditary spherocytosis (HS), 208–11, 209
hereditary stomatocytes (HST), 209, 211, 212
histogram plots, 11, 12
HIV (human immunodeficiency virus), 118, 132, 146, 214, 229
HLA-DR antigen, 48
HMDS (Haematology Malignancy Diagnostic Service), 28–9
Hodgkin lymphoma, 22, 175, 231
HS (hereditary spherocytosis), 208–11, 209
HSC see haematopoietic stem cells (HSC)
HST (hereditary stomatocytes), 209, 211, 212
HSTCL (hepatosplenetic T-cell lymphomas), 139–41, 145
HTLV (human T-cell leukaemia virus), 132
human immunodeficiency virus (HIV), 118, 132, 146, 214, 229
human T-cell leukaemia virus (HTLV), 132
hydrodynamic focusing, 4–5
hypoplastic myelodysplastic syndromes (MDS), 158, 233, 233
IM (infectious mononucleosis), 125, 226
immunodeficiency disorders
human immunodeficiency virus (HIV), 118, 132, 146, 214, 229
human T-cell leukaemia virus (HTLV), 132
inherited, 230–1, 230
immunoglobulin (Ig), 50, 82
infectious mononucleosis (IM), 125, 226
inherited functional granulocyte disorders, 215–19, 215
inherited immune deficiency disorders, 214, 231
inherited membrane disorder see hereditary spherocytosis (HS)
inherited platelet disorders, 219–21
instrument set-up, 15–18
internal quality assurance schemes (IQAS), 196, 199
internal quality control (IQC), 15–18
International PNH Interest Group, 202
International Prognostic Scoring System (IPSS), 155, 157
International Society for Haematotherapy and Graft Engineering (ISHAGE) protocol, 215
interpretation issues, 28–9
interrogation point, 4–5
intradacellular staining, 4
IPSS (International Prognostic Scoring System), 155, 157
IQAS (internal quality assurance schemes), 196, 199
IQC (internal quality control), 15–18
ISHAGE (International Society for Haematotherapy and Graft Engineering) protocol, 215
KB (Kleihauer–Betke) method, 213–14
killer cell immunoglobulin receptors (KIRs), 139
Kleihauer–Betke (KB) method, 213–14
LAP (leukaemia associated phenotype), 45
laser interrogation point, 4–5
leptomeningeal carcinomatosis (LC), 240
leptomeningeal disease, 89, 147
leptomeningeal disease, 89, 147
leukocyte adhesion disorder, 85, 114
leukocyte immunophenotyping programme, 18
leucocytes
anticoagulants, 20
differentiation, 6, 11
fluorescence/SSC plots, 6, 11
gating, 13
leucocytosis, 85, 114
in CMML, 163
post-splenectomy, 227
in T PLL, 129
leukaemia associated phenotype (LAP), 45
leukaemic stem cells (LSC), 51, 52
leukocyte adhesion disorder, 215
Levey–Jennings type plots, 18
light scatter, 5, 6
lineage assignment, 55
listmode files, 9
longpass (LP) filters, 8
LPD see chronic lymphoproliferative disorders (LPD)
LPL see lymphoplasmacytoid lymphoma
LSC (leukaemic stem cells), 51, 52
lumbar puncture (LP), 89
lymphoblastic leukaemia/lymphoma
see acute lymphoblastic leukaemia/lymphoma (ALL)
lymphocytes
analysis, 206
differentiation, 6, 11, 13
fluorescence/SSC plots, 6, 11
FSC/SSC plots, 12, 13, 14
normal peripheral blood, 100–1
subset analysis, 214
see also B-cells; natural killer (NK) cells; T-cells
lymphocytic leukaemia see chronic lymphocytic leukaemia (CLL)
lymphocytosis, 101, 103, 225–9
monoclonal B-cell lymphocytosis (MBL), 105
lymphoid maturation, 35–6
lymphopenia, 229–31
lymphoplasmacytoid lymphoma (LPL), 110–13, 178–80
CD5 expression in, 114
differentiation from myeloma, 180
differentiation from plasma cell disorders, 178–80
immunophenotype, 110–13
lymphoproliferative disorders see chronic lymphoproliferative disorders (LPD)lyse – no wash method, 3–4
mantle cell lymphoma (MCL), 105–7
CD5 expression in, 114
CNS involvement, 147
cytogenetics, 106, 110
immunophenotype, 105–6
morphology, 25, 105, 106
mast cell leukaemia see acute mast cell leukaemia
mast cells, 167, 168–9, 169
mastocytosis, 167–70, 167
MBL (monoclonal B-cell lymphocytosis), 105
MDS see myelodysplastic syndromes (MDS)
mean fluorescence intensity (MFI), 8
megakaryoblastic leukaemia see acute megakaryoblastic leukaemia
(MAML)
megakaryocytic maturation, 35
meningeval disease, 89, 90–1, 147
metastatic tumours, 28, 233, 236, 237, 240
MFI (mean fluorescence intensity), 8
MGUS see monoclonal gammopathy of undetermined significance (MGUS)
micro bead standards, 16–18
minimal residual disease (MRD), 184–201
acute leukaemia, 46, 51, 184
acute lymphoblastic leukaemia/lymphoma (ALL), 187–99
acute myeloid leukaemia (AML), 186–7
chronic lymphocytic leukaemia (CLL), 185–6
plasma cell disorders post transplant, 183
mixed lineage leukaemia (MLL), 54, 83, 84
mixed phenotype acute leukaemia (MPAL), 53, 54, 55, 166
MLL (mixed lineage leukaemia) rearrangements, 54, 83, 84
MM see multiple myeloma (MM)
monoclonal B-cell lymphocytosis (MBL), 105
monoclonal gammopathy of undetermined significance (MGUS), 173–4
differentiation from myeloma, 180
risk of progression, 180, 180, 182
monocytes
analysis, 205–6
differentiation, 6, 11
maturation, 33, 34
myelocytic leukaemias (AML M5), 57
CD2 expression in, 59
MPO expression in, 53
TdT expression in, 64
worked example, 62–3
monocytosis
in AML, 64
in CMML, 163, 165
morphological correlation, 28
MPAL (mixed phenotype acute leukaemia), 53, 54, 55, 166
MPN see myeloproliferative neoplasms (MPN)
MPO see myeloperoxidase (MPO)
MRD see minimal residual disease (MRD)
multiparameter flow cytometry, 13
multiple gates, 13
multiple myeloma (MM), 174, 175, 176, 177
CD20 positive, 179–80, 181
differentiation from lymphoplasmacytoid lymphoma, 178–80, 179
differentiation from MGUS, 180
prognosis, 182
MYC translocations, 46, 50, 83, 119
myelodysplastic syndromes (MDS), 152–63
classification, 154, 155
differentiation from AL, 43
differentiation from aplastic anaemia, 233
flow cytometry in, 155–62, 156
immunophenotypic abnormalities, 158, 159–62
paroxysmal nocturnal haemoglobinuria (PNH), 162, 207–8
prognosis, 155, 157
reduction in B-cell progenitors, 162
myelodysplastic/myeloproliferative neoplasms (MDS/MPN), 163–5
myelofibrosis, primary (PMF), 166–7
myeloid antigens, 52, 53, 53
in B-ALL, 83
in T-ALL, 86, 88
myeloid leukaemia, 58
aberrant antigen expression, 26
autofluorescence, 26
fluorescence, 8
gating, 26
see also acute myeloid leukaemia (AML); chronic myeloid leukaemia (CML)
myeloid lineage
maturation processes, 33–5
progenitor cell populations, 32, 33
T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL), 84–8
aberrant antigen expression, 86, 88
CD10 expression in, 82, 86
CD56 expression in, 65
CD79a expression in, 83
differentiation from AML, 45, 46
early T-precursor phenotype (ETP), 86
gene rearrangements, 82, 86
HLA-DR expression in, 84
immunological subclassification, 82
minimal residual disease, 193, 196
myeloid antigen expression in, 83
serous effusions, 23, 24
TdT expression in, 82
worked example, 87–8
T-cell disorders
CD4 positive, 128–36
acute T-cell leukaemia/lymphoma (ATLL), 131–2
anaplastic large cell lymphoma (ALCL), 132–3, 134
angio-immunoblastic T-cell lymphoma (AITL), 133–6
Sezary syndrome/cutaneous T-cell lymphoma (SS/CTCL), 128–9
summary table, 135
T-cell prolymphocytic leukaemia (T-PLL), 129–31
CD4/8 negative, 141–5
aggressive NK/T-cell neoplasms, 141–2, 143
enteropathy associated T-cell lymphoma (EATL), 142, 144, 145
hepatosplenic T-cell lymphomas (HSTCL), 145
peripheral T-cell lymphoma (PTCL), 145
CD4/CD8 positive, 141
CD8 positive, 136–41
hepatosplenic T-cell lymphomas (HSTCL), 139–41
natural killer cell (NK) chronic lymphoproliferations, 137–9, 140, 140
T-cell large granular lymphocyte leukaemia (T-LGL), 136–7, 138
T-prolymphocytic leukaemia, 141
CD56 positive, 136–7, 144
T-cell large granular lymphocyte leukaemia (T-LGL), 136–7, 138, 229
T-cell lymphoproliferative disorders antigen selection, 127
identification and diagnosis, 125–8
neoplasia induced lymphoid reactions, 229
T-cell prolymphocytic leukaemia (T-PLL), 126, 135, 141
T-cells
maturation processes, 36, 37
normal cell populations, 100
TdT (terminal deoxynucleotidyl transferase), 48
telangiectasia eruptive macularis perstans (TEMP), 168–9
TEMP (telangiectasia eruptive macularis perstans), 168–9
terminal deoxynucleotidyl transferase (TdT), 48
threshold setting, 9
T-LGL (T-cell large granular lymphocyte leukaemia), 136–7, 138, 229
T-lineage ALL see T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL)
T-lineage antigens, 53, 53
training, 25–7
transient abnormal myelopoiiesis (TAM), 58, 65
treatment response see minimal residual disease (MRD)
UK Flow MRD Working Group, 191, 193
UK National External Quality Assessment Service (NEQAS), 18
UKALL National Trials, 35, 188, 189
viral lymphocytosis, 226–7
Von-Willebrand disease, 220
WHO classification
acute leukaemia, 44, 46
AML subtypes, 56–8
B-ALL and T-ALL, 77, 84
lineage assignment, 53–4, 53
mastocytosis, 167
myelodysplastic syndromes (MDS), 154, 155
peripheral T-cell lymphoma (PTCL), 145
see also under headings for other specific disease entities